Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Eliminating the need for fasting with oral administration of bisphosphonates

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. New-onset of postoperative atrial fibrillation is likely to recur in the absence of other triggers

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Duration of hyperthyroidism and lack of sufficient treatment are associated with increased cardiovascular risk

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Over- and Under-Treatment of Hypothyroidism Is Associated with Excess Mortality: A Register-Based Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Women's lived experiences of learning to live with osteoporosis: a longitudinal qualitative study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Bisphosphonates are the major treatment of choice for osteoporosis, given that they are attached preferentially by bone and significantly reduce the risk of fractures. Oral bisphosphonates are poorly absorbed (usually less than 1% for nitrogen-containing bisphosphonates) and when taken with food or beverages create complexes that cannot be absorbed. For this reason, they must be taken on an empty stomach, and a period of up to 2 hours must elapse before the consumption of any food or drink other than plain water. This routine is not only inconvenient but can lead to discontinuation of treatment, and when mistakenly taken with food, may result in misdiagnosis of resistance to or failure of treatment. The development of an enteric-coated delayed-release formulation of risedronate with the addition of the calcium chelator, ethylenediaminetetraacetic acid (EDTA), a widely used food stabilizer, eliminates the need for fasting without affecting the bioavailability of risedronate or its efficacy.
Original languageEnglish
JournalTherapeutics and Clinical Risk Management (Online)
Volume9
Pages (from-to)395-402
Number of pages8
ISSN1176-6336
DOIs
Publication statusPublished - 2013

ID: 40877261